Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

This phase 2 study was designed to compare systemic decitabine exposure, demethylation activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs standard decitabine 20 mg/m(2) IV. Adults with International Prognostic Scoring System intermediate-1/2- or high-risk myelody...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Garcia-Manero, Guillermo, Griffiths, Elizabeth A., Steensma, David P., Roboz, Gail J., Wells, Richard, McCloskey, James, Odenike, Olatoyosi, DeZern, Amy E., Yee, Karen, Busque, Lambert, O’Connell, Casey, Michaelis, Laura C., Brandwein, Joseph, Kantarjian, Hagop, Oganesian, Aram, Azab, Mohammad, Savona, Michael R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7414597/
https://ncbi.nlm.nih.gov/pubmed/32285126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019004143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados